Ozempic (semaglutide)

pCPA File Number: 21094
Negotiation Status:
Concluded with an LOI
Indication(s):
Diabetes Mellitus, Type 2
Sponsor/Manufacturer:
Novo Nordisk Canada Inc.
CDA-AMC Project Number:
SR0594-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: